{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:31:00Z","timestamp":1790667060589,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2020CFB397"],"award-info":[{"award-number":["2020CFB397"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The prognosis of patients with relapsed Ewing sarcoma is poor. In this study, we aimed to pooled-analyze the efficacy and safety of the combination of irinotecan and temozolomide in treating patients with relapsed Ewing sarcoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PubMed, Cochrane CENTRAL, Web of Science, and EMBASE were systematically searched on September 27, 2021. The primary outcomes were rates of objective response and disease control, and the secondary outcomes were toxicities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Six retrospective studies with 184 patients were enrolled in the analysis. The median age ranged from 14 to 21. The integrated rates were 44% (95% confidence interval [CI] 31\u201358) for objective response and 66% (55\u201377) for disease control. Grade 3\u20134 neutropenia, thrombocytopenia, and diarrhea occurred in 8% (3\u201316), 7% (3\u201311), and 8% (5\u201310) of chemotherapeutic cycles, respectively. 18% (7\u201332) and 6% (2\u201311) of patients suffered grade 3\u20134 neutropenia and thrombocytopenia after irinotecan plus temozolomide treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Irinotecan plus temozolomide combination chemotherapy showed antitumor activity and an acceptable safety profile in patients with relapsed Ewing sarcoma. More future prospective studies are needed to confirm the retrospective results.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09469-5","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:04:04Z","timestamp":1648717444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies"],"prefix":"10.1186","volume":"22","author":[{"given":"Bi-Cheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Ya","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-He","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"issue":"8","key":"9469_CR1","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.joms.2005.04.014","volume":"63","author":"SJ Alrawi","year":"2005","unstructured":"Alrawi SJ, Tan D, Sullivan M, Winston J, Loree T, Hicks W, Rigual N. Peripheral primitive neuroectodermal tumor of the mandible with cytogenetic and molecular biology aberrations. J Oral Maxillofac Surg. 2005;63(8):1216\u201321.","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"9469_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s002920050129","volume":"17","author":"A Roessner","year":"1996","unstructured":"Roessner A, Mittler U, Rose I, Radig K, Grote H. Pathology of Ewing sarcoma. Pathologe. 1996;17(1):6\u201317.","journal-title":"Pathologe"},{"key":"9469_CR3","doi-asserted-by":"crossref","unstructured":"Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M, Evans R, Thomas P, Askin FB, Kissane JM, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing\u2019s sarcoma of bone: a long-term follow-up of the first Intergroup study. J Clin Oncol. 1990;8(10):1664\u201374.","DOI":"10.1200\/JCO.1990.8.10.1664"},{"key":"9469_CR4","doi-asserted-by":"crossref","unstructured":"Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694\u2013701.","DOI":"10.1056\/NEJMoa020890"},{"key":"9469_CR5","doi-asserted-by":"crossref","unstructured":"Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the children\u2019s oncology group. J Clin Oncol. 2012;30(33):4148\u201354.","DOI":"10.1200\/JCO.2011.41.5703"},{"key":"9469_CR6","unstructured":"Bone Cancer (Version 1, 2022) [https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bone.pdf]"},{"issue":"12","key":"9469_CR7","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.3390\/cancers13123046","volume":"13","author":"SD Asaftei","year":"2021","unstructured":"Asaftei SD, Puma N, Paioli A, Petraz M, Morosi C, Podda M, Tamburini A, Palmerini E, Coccoli L, Grignani G, et al. Front-line window therapy with temozolomide and irinotecan in patients with primary disseminated multifocal Ewing Sarcoma: results of the ISG\/AIEOP EW-2 study. Cancers. 2021;13(12):3046.","journal-title":"Cancers"},{"issue":"15_suppl","key":"9469_CR8","doi-asserted-by":"publisher","first-page":"11502","DOI":"10.1200\/JCO.2020.38.15_suppl.11502","volume":"38","author":"MG McCabe","year":"2020","unstructured":"McCabe MG, Kirton L, Khan M, Fenwick N, Dirksen U, Gaspar N, Kanerva J, Kuehne T, Longhi A, Luksch R, et al. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). J Clin Oncol. 2020;38(15_suppl):11502\u201311502.","journal-title":"J Clin Oncol"},{"issue":"2","key":"9469_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/pbc.20697","volume":"48","author":"LM Wagner","year":"2007","unstructured":"Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, Albritton K. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007;48(2):132\u20139.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"9469_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/pbc.22206","volume":"53","author":"DA Casey","year":"2009","unstructured":"Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, Meyers PA. Irinotecan and temozolomide for Ewing Sarcoma: the memorial sloan-kettering experience. Pediatr Blood Cancer. 2009;53(6):1029\u201334.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"9469_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/08880018.2014.954070","volume":"32","author":"N Kurucu","year":"2015","unstructured":"Kurucu N, Sari N, Ilhan IE. Irinotecan and temozolamide treatment for relapsed Ewing Sarcoma: a single-center experience and review of the literature. Pediatr Hematol Oncol. 2015;32(1):50\u20139.","journal-title":"Pediatr Hematol Oncol"},{"issue":"7","key":"9469_CR12","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1080\/0284186X.2018.1449250","volume":"57","author":"E Palmerini","year":"2018","unstructured":"Palmerini E, Jones RL, Setola E, Picci P, Marchesi E, Luksch R, Grignani G, Cesari M, Longhi A, Abate ME, et al. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. Acta Oncol. 2018;57(7):958\u201364.","journal-title":"Acta Oncol"},{"issue":"4","key":"9469_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s12094-020-02466-9","volume":"23","author":"S Salah","year":"2021","unstructured":"Salah S, To YH, Khozouz O, Ismail T, Yaser S, Alnsour A, Shahin O, Sultan I, Abuhijlih R, Halalsheh H, et al. Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. Clin Transl Oncol. 2021;23(4):757\u201363.","journal-title":"Clin Transl Oncol"},{"key":"9469_CR14","doi-asserted-by":"crossref","unstructured":"Anderson P, Kopp L, Anderson N, Cornelius K, Herzog C, Hughes D, Htth W. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing\u2019s sarcoma and osteosareoma). Expert Opin Investig Drugs. 2008;17(11):1703\u201315.","DOI":"10.1517\/13543784.17.11.1703"},{"issue":"3","key":"9469_CR15","first-page":"e123","volume":"3","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123-130.","journal-title":"Open Med"},{"key":"9469_CR16","volume-title":"Introduction tometa-analysis[M]: Chichester: John Wiley&Sons","author":"M HL Borenstein","year":"2009","unstructured":"Borenstein M HL, Higgins JPT, et al. Introduction tometa-analysis[M]: Chichester: John Wiley&Sons. 2009."},{"key":"9469_CR17","unstructured":"Package'meta'[EB\/OL] [http:\/\/cran.r-project.org.whuh.vpn358.com\/web\/packages\/meta\/Index.html]"},{"issue":"10","key":"9469_CR18","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/pbc.24621","volume":"60","author":"A Raciborska","year":"2013","unstructured":"Raciborska A, Bilska K, Drabko K, Chaber R, Pogorzala M, Wyrobek E, Polczy\u0144ska K, Rogowska E, Rodriguez-Galindo C, Wozniak W. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 2013;60(10):1621\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"9469_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejca.2020.06.014","volume":"137","author":"SM Federico","year":"2020","unstructured":"Federico SM, Pappo AS, Sahr N, Sykes A, Campagne O, Stewart CF, Clay MR, Bahrami A, McCarville MB, Kaste SC, et al. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer. 2020;137:204\u201313.","journal-title":"Eur J Cancer"},{"issue":"8","key":"9469_CR20","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/cncr.33349","volume":"127","author":"R Chugh","year":"2021","unstructured":"Chugh R, Ballman KV, Helman LJ, Patel S, Whelan JS, Widemann B, Lu Y, Hawkins DS, Mascarenhas L, Glod JW, et al. SARC025 arms 1 and 2: a phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer. 2021;127(8):1301\u201310.","journal-title":"Cancer"},{"issue":"6","key":"9469_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/pbc.20719","volume":"47","author":"A Hunold","year":"2006","unstructured":"Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jurgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer. 2006;47(6):795\u2013800.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"9469_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/MPH.0b013e318270a343","volume":"35","author":"R Farhat","year":"2013","unstructured":"Farhat R, Raad R, Khoury NJ, Feghaly J, Eid T, Muwakkit S, Abboud M, El-Solh H, Saab R. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution. J Pediatr Hematol Oncol. 2013;35(5):356\u201360.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"9469_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/pbc.21917","volume":"52","author":"S Ferrari","year":"2009","unstructured":"Ferrari S, del Prever AB, Palmerini E, Staals E, Berta M, Balladelli A, Picci P, Fagioli F, Bacci G, Vanel D. Response to high-dose ifosfamide in patients with advanced\/recurrent Ewing sarcoma. Pediatr Blood Cancer. 2009;52(5):581\u20134.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"9469_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","volume":"21","author":"A Italiano","year":"2020","unstructured":"Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werle N, Saada E, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(3):446\u201355.","journal-title":"Lancet Oncol"},{"issue":"2","key":"9469_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/cncr.23586","volume":"113","author":"F Navid","year":"2008","unstructured":"Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113(2):419\u201325.","journal-title":"Cancer"},{"key":"9469_CR26","doi-asserted-by":"crossref","unstructured":"Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent\/refractory sarcoma: the Children\u2019s Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005;44(4):338\u201347.","DOI":"10.1002\/pbc.20227"},{"issue":"6","key":"9469_CR27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/bjc.2017.252","volume":"117","author":"J Mora","year":"2017","unstructured":"Mora J, Casta\u00f1eda A, Perez-Jaume S, Lopez-Pousa A, Maradiegue E, Valverde C, Martin-Broto J, del GarciaMuro X, Cruz O, Cruz J, et al. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). Br J Cancer. 2017;117(6):767\u201374.","journal-title":"Br J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09469-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09469-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09469-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:10:53Z","timestamp":1648717853000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09469-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9469"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09469-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"12 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"349"}}